OSCR — All updates

4 entries loaded; 0 direction changes

Filter loaded records
The Motley FoolPublished 2026-11-13
“5 Stocks Set to Soar in 2027”
$OSCRNo side taken
AI summary · Oscar Health's future direction looks promising, but the speaker has stayed out because Washington's decisions on the ACA and its funding — outside the company's control — could profoundly affect the business and cause volatility, and he doesn't know how they will turn out. He has considered a small position that could become a full one after a major downturn; OSCR is on his 2027 radar.

think that's probably the future direction , and it's good for Oscar Health . The only reason I couldn't support Oscar Health as a shareholder is the risks I see in the regulatory landscape.

I am only concerned about what the legislators might do, which will have a significant and profound impact on Oscar Health's business, and this is something completely out of the company's control, i.e., what Washington decides to do.

The Motley FoolPublished 2026-11-10
“Stock Market Update: Rising Rates & Falling Stocks”
$OSCRBullish
AI summary · OSCR had another good quarter and raised full-year guidance: revenue to $19–19.3B from $18.7–19B, operating earnings outlook up, and medical loss ratio expected at 80.5–81.5%; management says it is on track for its strongest financial year and is profitable and growing quickly. The speaker likes where OSCR is headed, citing Mark’s leadership and a compelling ICRA marketplace model, but does not own shares yet and wishes he had bought around $20.

They they did report last week. It was another pretty good quarter. Let me see if I can remember. Um I think they they might have raised guidance again. Yeah, I think outlook was was raised.

Um they're now looking at between 19 to 19.3 billion in revenue. That's up from $18.7 to19 billion. Uh earnings from operations is also up for the full full year outlook. Medical cost rat medical loss loss ratio is now expected to be between 80.5 to 81.5.

So slight improvement there. Um co said they're on track to deliver the strongest year of financial performance in their history. They actually generate profit. They're growing quite quickly.

Parkev Tatevosian, CFAPublished 2026-09-28
“3 Undervalued Healthcare Stocks Invstors Can Buy Right Now”
$OSCRBullish
AI summary · OSCR is undervalued; fair value >$41 vs price ~$30 implies >34% upside in 12-18 months driven by growth and cost control.

Last but not least, Oscar Health, one of the top healthcare companies in terms of integrating artificial intelligence into its operations to improve efficiency and performance.

It is one of the fastest growing healthcare companies since 2024. It has achieved a compound annual revenue growth rate of over 40%. Management anticipates compound annual revenue growth rates exceeding 20% from now until 2030.

It is controlling costs, and profits are improving as a result of this expansion in revenue and net profit.

Chip Stock InvestorPublished 2026-09-03
“Why Oscar Health's 'Great Quarter' Isn't What It Looks Like”
$OSCRBearish
AI summary · OSCR is not cheap and not a buy; FCF is misleading for insurers as funds are not permanently retained.

Oscar Health, which is a health insurance company, had a really great quarter. They've got fantastic revenue. Their subscriber base is growing. Free cash flow is positive. Everything looks great.

How do you run a reverse DCF on that company? What terminal rate would you use for a company like this? And so that got us thinking about how we would go about looking at this.

That's the earliest record
All updates for other tickers
Follow $OSCR30-day free trial
Start trial